HHS Secretary defends eliminating required health benefits

In an interview with CNN, HHS Secretary Tom Price, MD, continued to defend Republican alternatives to the Affordable Care Act (ACA), calling the American Health Care Act (AHCA) “a significantly better program than the one we currently have.”

The AHCA was pulled before the full House of Representatives could vote on the bill. It had faced opposition from almost all major medical organizations, particularly over the elimination of the ACA’s “essential health benefits” that insurers are required to cover, including hospitalization. When asked by CNN’s Sanjay Gupta, MD, about whether it’s an improvement to allow “skimpy plans” which don’t cover those services, Price said it offers more choices for coverage to those who have chosen to remain uninsured.  

“You’ve got 20 million people in this country who have said, ‘Nonsense. I’m not going to be forced to do what you want me to do because I don’t believe it’s necessary for me,’” Price said.

Price also indicated Republicans will continue working on a ACA replacement, saying that despite the last effort failing to gain the support it needed in the House, “there’s always a ‘Plan B.’”

Watch more of the interview at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.